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jvc.2010.06.005Abstract Objectives: To retrospectively compare and contrast the clinical
presentation, diagnostic findings and survival in Boxer dogs with cardiomyopathy,
with or without left ventricular (LV) systolic failure.
Animals, materials and methods: Medical records of Boxers referred between 1993
and 2008 in which a diagnosis of ventricular arrhythmias and/or cardiomyopathy was
made, were reviewed. Dogs were divided into two groups according to their left
ventricular (LV) systolicdiameter, groupAnormal (20dogs)orgroupBdilated(59dogs).
Results: Dogs in group A had a better outcome than dogs in group B (median survival
time of 124 and 17 weeks respectively, p < 0.001). In group B, dogs with a history of
collapse had a worse outcome (median survival time of 10 weeks) compared with dogs
not showing collapse (median survival time 24 weeks) (p ¼ 0.031).
Conclusions: The majority of dogs, in this UK study, presented with the myocardial
dysfunction form of the disease, with LV dilation and congestive heart failure signs.
The prognosis was worse in dogs with LV dilation compared to dogs with a normal LV
and ventricular arrhythmias. In the Boxers with LV dilation, dogs with collapse had
a worse prognosis than those without.
ª 2011 Elsevier B.V. All rights reserved.@ed.ac.uk (V. Palermo).
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Much research has been carried out to try toHarpster first described “Boxer cardiomyopathy”
(BCM) in 1983 proposing three clinical categories of
the disease: concealed, overt and a myocardial
dysfunction form.1 The concealed form is charac-
terized by the absence of clinical signs but pres-
ence of ventricular premature complexes (VPCs).
In the overt form, syncope or episodic weakness
and tachyarrhythmias are present, while the third
group is characterized by myocardial systolic
dysfunction (affecting mainly the left ventricle)
sometimes with congestive heart failure (CHF) and
arrhythmias.1e3
Boxer cardiomyopathy has been characterized
as a degenerative myocardial disease with exten-
sive and unique right ventricular histologic findings
that include myocyte atrophy and fatty infiltra-
tion.1 Similarities in clinical presentation, patho-
logical findings and presumed aetiology with
a human myocardial disease called arrhythmo-
genic right ventricular cardiomyopathy, have sug-
gested reclassification of the disease as Boxer
arrhythmogenic right ventricular cardiomyopathy
(ARVC).3,4
In Boxers, ARVC is an adult-onset familial
disease apparently inherited as an autosomal
dominant trait.5 ARVC is primarily an electrical
disease sometimes associated with myocardial
dysfunction. Diagnosis is best based on a combina-
tion of findings that may include a family history of
disease, a history of syncope, presence of
ventricular tachyarrhythmias with a left bundle
branch block (LBBB) morphology or post mortem
findings. Most affected dogs have a normal echo-
cardiographic examination, particularly with
regard to evaluation of the size and function of the
left ventricle.3
Idiopathic dilated cardiomyopathy (DCM) is
a primary myocardial disorder characterized by
reduced contractility and ventricular dilation
involving the left ventricle or both ventricles, of
unknown or uncertain aetiology.6,7 Some Boxer
dogs have a clinical and echocardiographic
presentation consistent with idiopathic dilated
cardiomyopathy, of which the etiology is unknown.
Harpster refers to these cases as the myocardial
dysfunction form (category 3) which is considered
to be less common.3
Whether the three forms proposed by Harpster
represent a continuum of the disease has not been
well documented and it is also not clear how many,
if any, cases of cardiomyopathy in Boxers are due
to “conventional” idiopathic DCM or other forms of
myocardial disease.identify a mutation or genetic abnormality linked
to ARVC. In cardiomyopathic Boxer dogs myocar-
dial calstabin2 mRNA and protein were signifi-
cantly decreased as compared to healthy control
dogs8 and recently a 7 base pair deletion in
a regulatory region of a calcium modulating gene
was identified and observed to be highly associ-
ated with the disease status.9
There are few publications describing pop-
ulations of Boxers affected by cardiomyopathy and
the majority were reported by Harpster in 1983
and 1991.1,2 Moreover, most of the more recent
work on ARVC comes from the USA9e17 and no
survival studies are available.
The aim of this study was to retrospectively
evaluate signalment, clinical and diagnostic find-
ings, survival and prognostic factors in a pop-
ulation of Boxer dogs with cardiomyopathy from
the UK, in order to improve our knowledge of this
disease. Given the difficulties in differentiating
ARVC from idiopathic DCM affected Boxers were
divided into two groups according to their left
ventricular systolic diameter, either normal or
increased. The two groups were then compared in
terms of presentation, outcome and possible
relationship between the two populations.Materials and methods
Medical records of client-owned Boxer dogs
referred to the Veterinary Cardiorespiratory
Centre, Kenilworth, UK, between January 1993
and July 2008, in which a diagnosis of cardiomy-
opathy or ventricular arrhythmia had been made,
were reviewed. Only dogs that were referred with
a clinical history or presence of a clinical or ECG
abnormality were included in the study. Dogs
examined for routine breed screening were
excluded. Information obtained included: age,
sex, clinical presentation; results of standard
6-lead electrocardiography (HR, rhythm, presence
and morphology of VPCs), 24-h Holter monitoring,
thoracic radiography, Doppler echocardiography
and survival time.
Diagnosis of cardiomyopathy was based on
a combination of factors including a history of
syncope or exercise intolerance, presence of ECG
and/or Holter abnormalities (number and
complexity of VPCs) and echocardiographic
examination.3 Dogs in which an ECG was not per-
formed, but that underwent a Holter study, as well
as dogs in which ECG was performed by the
primary veterinarian and returned (thus not
Cardiomyopathy in Boxer dogs 47available for our retrospective analysis, but the
findings were present in the medical record) were
included. We used a modification of the Holter
ventricular arrhythmia classification grading
defined by Meurs3 including arrhythmias present on
both ECG and Holter as detailed in Table 1. Dogs
were excluded if there was gross left atrial dilation
(i.e. significantly larger than the diameter of the
left ventricle in diastole) that could suggest
primary mitral valve disease.6 Dogs with aortic
velocity > 2.4 m/s, with congenital or other
acquired heart diseases, myocardial failure
secondary to rapid supraventricular tachycardia
(where myocardial function returned to normal
after the arrhythmia was controlled), or systemic
diseases that might affect the cardiovascular
system (e.g. hypothyroidism) were excluded.
Doppler echocardiographic examinations were
performed according to standard criteria for
dogs18 (with continuous ECG monitoring). Left
ventricular measurements were compared to
normal values for the Boxer dog19 and for the
purposes of this study, dogs were divided into two
groups based on echocardiographic measurement
(M-mode and 2-D) of the systolic left ventricular
diameter. When M-mode and 2-D measurements
were different, the larger value was used. Group
A: dogs with a systolic LV internal diameter <
35 mm were defined as normal and group B: dogs
with systolic LV internal diameter > 35 mm were
defined as dilated. Additionally, to compare the
usefulness of the cut-off chosen in this study, left
ventricular measurements were evaluated using an
allometric scale20 and the echocardiographic ratio
indices (ERIs).21
Left atrial (LA) measurements in both long and
short axis views were recorded and compared to
published normal values.22 Right ventricular
chamber size was subjectively assessed by
comparison with the left ventricle in the right
parasternal long-axis view and left apical view.Table 1 ECG and Holter arrhythmia classification.
ECG class 1 Single VPCs
ECG class 2 Couplets/triplets
ECG class 3 VT
Holter class 1 <1000 single VPCs/24 h
Holter class 2 >1000 single VPCs/24 h
Holter class 3 <1000 VPCs/24 h,
couplets, triplets, VT
Holter class 4 >1000 VPCs/24 h,
couplets, triplets, VT
VPCs, ventricular premature complexes; VT, ventricular
tachycardia.Right ventricular dilation was defined as follows:
mild dilation if it was between 30 and 50% of left
ventricular size, moderate dilation if it was from
50 to 100% of left ventricular size, and severe
dilation when right ventricular size exceeded that
of the left ventricle. Assessment of cardiomegaly
on thoracic radiography was based on the verte-
bral heart scale system (VHS)23 and clinical expe-
rience, and the presence of signs of congestive
heart failure (pulmonary venous congestion or
pulmonary oedema) was recorded.
Date and cause of death (either spontaneous
death or euthanasia) were recorded and survival
time was measured from the date of referral. Dogs
euthanized for severe chronic heart failure were
considered as cardiac-related deaths. Sudden
deaths were counted as cardiac-related if no other
cause of death was obvious. Dogs still alive, dogs
that died or were euthanized for reasons unrelated
to cardiac disease were censored in the statistical
analysis; subjects lost to follow-up were included
in the survival analysis up until the last time point
at which they were known to be alive and then
were thereafter censored in the analysis.Statistical analysis
Continuous variables were assessed for significant
differences between the groups. The ShapiroeWilk
test was used to verify variables’ normal distribu-
tion. If the distribution was normal, a t-test was
used to compare the means of two continuous
variables; the ManneWhitney U test was used
with non-normally distributed variables. The
KaplaneMeier method was used to estimate
survival function and plot time to event curves.
After accepting the assumption of proportional
hazards, multivariate Cox proportional hazards
analysis was performed to determine whether any
variable was associated with survival time, in each
group separately first, then in the whole sample.
Variables assessed for their effect on outcome in
the whole sample were: group, presence of
ventricular arrhythmias (considering both ECG
trace and Holter study), ECG class, presence of
ventricular tachycardia (VT) (considering both ECG
and Holter study) and collapse. ECG class and
collapse were assessed in group A; presence of
ventricular arrhythmias, presence of VT, ECG
class, and collapse were assessed in group B.
Hazard ratio (HzR) and 95% confidence intervals
(CI) were calculated. A Pearson’s chi-square test
was used to assess a significant association
between the presence of ventricular arrhythmias
and syncope or the presence of VT and syncope.
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descriptive statistical analyses were performed
using Microsoft Excel, Cox proportional hazard
and survival analyses were performed with
a commercially available software program (SPSS
version 17).Results
A total of 79 dogs met the inclusion criteria for the
study; there were 20 in group A and 59 in group B.
Males were overrepresented with a M:F ratio of
1.9: 1 in group A and 1.4: 1 in group B. Mean (SD)
age at presentation was 91.7 months (32.2)
(range 20e122) in group A and 68.6 months (28.6)
(range 8e120) in group B; age distribution is shown
in Fig. 1 and Table 2.
The median (interquartile range) duration of
clinical signs prior to referral was 2 weeks (1e3.25;
range 0e72) in group A and 4 weeks (2e8; range
1e104) in group B. Two dogs in group B had a long
duration of clinical signs before referral; the
reported signs were collapse, exercise intolerance
and weakness. Although these signs can be repor-
ted in dogs with congestive heart failure, consid-
ering their long duration, they are probably more
typical of category 2 ARVC.
The most common presenting clinical sign in
both groups was collapse (80% and 67.7% in group A
and B respectively); cough, breathlessness and
exercise intolerance were more common in group
B dogs. On clinical examination a systolic murmur
was present in 6/20 patients in group A (grade I/VI
in 4 dogs, grade II in 1 dog, grade III in 1 dog) and in
22/59 dogs in group B (grade I in 12 dogs, grade II in
6 dogs, grade III in 3 dogs, grade IV in 1 dog). Pallor
of the mucous membranes and a weak pulse were
noted in dogs of both groups, while gallop rhythm
and ascites were present only in group B dogs. TheFigure 1 Distribution of age at presentation (years) for
group A and B dogs.presence of an arrhythmia on clinical examination
was not recorded in the clinical records in the
majority of dogs, but was detected on ECG and/or
Holter recording; it is impossible to know the real
prevalence of this clinical finding, therefore we
decided not to evaluate this. Signalment, clinical
signs and physical examination findings for all dogs
are displayed in Table 2.
Electrocardiograms were available for review in
18/20 and 57/59 dogs in group A and B respec-
tively. Mean (SD) heart rate was 133.5 (26.8) bpm
in group A and 171.6 (45.6) bpm in group B. In both
groups VPCs were the most commonly recorded
arrhythmia, mainly present as single VPCs (ECG
class 1), but the prevalence was higher in group A.
In group B, supraventricular premature complexes
(SVPCs) and atrial fibrillation (AF) were also
present (Fig. 2). Holter monitoring was performed
in 10 dogs in group A and 7 in group B. In 6 dogs of
group A which underwent both a standard ECG and
Holter recording, the ECG tracing was graded as
class 1 (single VPCs) whereas the Holter showed
a high number of VPCs with increased complexity
and periods of ventricular tachycardia (Holter
class 2 in 1 dog, class 3 in 1 dog, class 4 in 4 dogs).
In group B, in 3 cases Holter monitoring demon-
strated the presence of VT, not evident on ECG and
in 2 dogs where the ECG was normal, VPCs were
demonstrated by Holter. ECG and Holter findings
for both groups are displayed in Table 3.
Morphology of VPCs seen on a lead II ECG or on
Holter was consistent with LBBB morphology in the
majority of patients in both groups and right
bundle branch morphology (RBBB) was more
frequent in group B dogs (Fig. 3).
Thoracic radiographs were performed in 12 dogs
in group A and 51 dogs in group B and revealed the
presence of cardiomegaly in 82.3% of dogs in group
B, associated with signs of pulmonary oedema in
58.8%; in group A, 1 dog showed cardiomegaly.
Echocardiographic examination revealed mild/
moderate right ventricular (RV) enlargement,
mitral and/or tricuspid regurgitation in a small
percentage of boxers in group A (mild/moderate
RV enlargement in 10% and 5% respectively, mitral
regurgitation in 5% and tricuspid regurgitation or
both in 10%). In group B concurrent RV dilation was
uncommon and mitral and tricuspid insufficiency
were common (mitral regurgitation in 38.9% and
both mitral and tricuspid regurgitation in 40.6%).
Mean LVDs (SD) was 29.7 (4.1) and 48 (6.6) mm
respectively for group A and group B dogs. The
Cornell index for the LVIDs was in the normal range
(0.71e1.26)20 in all the dogs in group A and group B
dogs had values outside this range. Using the ERIs
proposed for the Boxer breed, all the dogs in group
Table 2 Signalment in the whole population and groups; presenting signs and clin-
ical examination findings in groups A and B.
Whole
population
Group A
(LVDs <35 mm)
Group B
(LVDs >35 mm)
Number of dogs 79 20 59
Male 60.7% 65% 59.3%
Female 39.3% 35% 40.6%
Ratio M:F 1.5:1 1.9:1 1.4:1
BW (Kg) mean  SD 30.3  4.7 32.5  3.7 29.7  4.6
Age (months) mean  SD 74.5  31.1 91.7  32.2 68.6  28.6
Clinical findings
Cough 15% 64.4%
Breathlessness 30% 55.9%
Exercise intolerance 20% 55.9%
Collapse 80% 67.7%
Weakness 30% 38.9%
Lethargy 0 15.2%
Poor appetite 5% 28.8%
Weight loss 5% 30.5%
Murmur 30% 37.2%
Gallop sounds 0 11.4%
Weak pulse 10% 30.5%
Pallor 25% 15.2%
Ascites 0 16.9%
Cardiomyopathy in Boxer dogs 49A presented a weight-based LVIDs (WLVIDs) in the
proposed normal range (0.68e1.35),21 while all the
dogs in group B had a WLVIDs out of the normal
range. Echocardiographic findings are displayed in
Table 4.
Three dogs were still alive at the end of the
study and 8 dogs were lost to follow-up. Sixty-
three dogs died or were euthanized for cardiac
reasons (11 in group A, 52 in group B) and 5 dogs
died or were euthanized for reasons unrelated to
cardiomyopathy (leukemia, mammary neoplasia,
epilepsy (2 dogs), heart-base neoplasia) (4 in group
A and 1 in group B). A total of 75 dogs were
available for survival analysis.
As expected because of the division into groups
based on LV diameter, groups differed significantly
for all other echocardiographic parameters: leftFigure 2 Prevalence of arrhythmias (%) in dogs of
group A and B. VPCs, ventricular premature complexes;
SVPCs, supraventricular premature complexes; AF, atrial
fibrillation.ventricular diameter in diastole (LVDd), fractional
shortening (FS%), LA diameter in long-axis view, LA
diameter in short axis view (P < 0.001). Further-
more age (P ¼ 0.002) and heart rate (P < 0.001)
were significantly different between groups.
Comparing survival times, dogs in group A had
a better outcome than dogs in group B. Median
survival time was 124 weeks (95% CI ¼ 46.7e201.3)
for group A dogs and 17 weeks (95%
CI ¼ 14.6e19.4) for group B dogs (P < 0.001)
(Fig. 4). Hazard ratio of group A compared to group
B was 0.207 (95% CI ¼ 0.103e0.418). Other vari-
ables ECG class (P ¼ 0.36), ventricular arrhythmias
(P ¼ 0.48), VT (P ¼ 0.36), collapse (P ¼ 0.47) did
not have a significant effect on the risk of cardiac-
related death. No significant association was found
between the presence of VPCs and syncope
(P ¼ 0.07) or presence of VT and syncopeTable 3 ECG and Holter findings in groups A and B.
Group A Group B
Mean HR (bpm) 133.5  26.8 171.6  45.6
ECG class 1 72.2% 51.6%
ECG class 2 0 22.6%
ECG class 3 27.8% 25.8%
Holter class 1 2/10 1/7
Holter class 2 1/10 1/7
Holter class 3 1/10 2/7
Holter class 4 6/10 3/7
Figure 3 Morphology of VPCs on ECG/Holter in dogs of
group A and B. LBBB, left bundle branch block; RBBB,
right bundle branch block.
Figure 4 KaplaneMeier survival curve in the overall
population of dogs (group A and B). Dogs in group A
(normal left ventricle) had a median survival time of 124
weeks (95% CI ¼ 46.7e201.3), dogs in group B (dilated
left ventricle) had a median survival time of 17 weeks
(95% CI ¼ 14.6e19.4) (P < 0.0001).
50 V. Palermo et al.(P ¼ 0.29). In group A no variable was significantly
associated with survival when considering cardiac-
related deaths (ECG class P ¼ 0.21, collapse
P ¼ 0.86). In group B dogs the only variable that
was significantly associated with outcome was the
presence of collapse (P ¼ 0.031); dogs in which
a history of collapse was present had a worse
outcome with a median survival time of 10 weeks
(95% CI ¼ 0e21.3) compared with dogs not showing
collapse (median survival time 24 weeks, 95%
CI ¼ 15.5e32.5) (Fig. 5). Hazard ratio of dogs with
a history of collapse was 1.931 (95%
CI ¼ 1.060e3.521). Other variables ECG class
(P ¼ 0.09), presence of ventricular arrhythmias
(P ¼ 0.17), presence of VT (P ¼ 0.058) were not
significant, although VT was close to the chosen 5%
level of significance.Table 4 Echocardiographicfindings in groups A andB.
Group A Group B
LVDd (mm)
mean  SD
39.1  5.1 54.2  6.9
LVDs (mm)
mean  SD
29.7  4.1 48  6.6
FS (%)mean  SD 25.8  7.4 11.8  5.4
LA long-axis (mm)
mean  SD
39.8  5.4 54.7  6.9
LA short axis (mm)
mean  SD
35.8  9.3 48.9  7.7
Mild RV dilation 10% 15.2%
Moderate RV
dilation
5% 8.4%
MR only 5% 38.9%
TR only 10% 0
MR þ TR 10% 40.6%
LVDd, left ventricular diameter diastole; LVDs, left ventric-
ular diameter systole; FS, fraction shortening; LA, left
atrium; RV, right ventricle; MR, mitral regurgitation; TR,
tricuspid regurgitation.Discussion
Boxer cardiomyopathy in the UK has close simi-
larities to the disease in the USA, but there seems
to be a different prevalence of the three Harp-
ster’s categories in the 2 countries. Meurs reportedFigure 5 KaplaneMeier survival curve in group B dogs.
Dogs in which collapse was present (1) had a median
survival time of 10 weeks (95% CI ¼ 0e21.3), dogs
without collapse (0) had a median survival time of 24
weeks (95% CI ¼ 15.5e32.5) (P ¼ 0.031).
Cardiomyopathy in Boxer dogs 51that only a small percentage of adult Boxers with
tachyarrhythmias are observed to have LV dilation
with systolic dysfunction3 and Harpster reported
an almost equal distribution of dogs in his 3 cate-
gories.1,2 Our work showed a different distribution
of dogs, with most of the dogs having the
myocardial dysfunction form with LV dilation and
signs of CHF. As suggested by Wotton this could be
due to a different prevalence of the “DCM type” in
the UK and USA; BCM in the UK may be less
genetically widespread in the breed than in the
USA, appearing to be effectively restricted to
three family lines (all with American ancestry)
with an autosomal dominant pattern of
inheritance.24
The signalment for the dogs in this study was
similar to that reported in previous publications.
For all dogs, males were more commonly affected
than females which is similar to Harpster’s find-
ings.1,2 In both groups A and B, males were over-
represented. The difference between males and
females in group B was not as marked as in group
A, in partial agreement with previous studies of
Boxers with LV dysfunction which reported
a gender ratio of 50:50 M:F25 and 45:55 M:F.15 In
group A, a male predominance was evident, sug-
gesting a predisposition in males to ventricular
arrhythmias or lesser likelihood of males pro-
gressing to CHF. Mean age at presentation in the
whole population and in the subgroups was similar
to that reported by Harpster,1,2 by Basso et al.4 in
Boxers with arrhythmias and by Baumwart et al.15
in Boxers with LV dysfunction. Mean age differed
significantly between group A and group B dogs,
with group A dogs being older than group B.
Therefore it would seem difficult to believe from
this result that group B dogs represent an
advanced, and thus subsequent, stage of the
disease.
The main difference in the presenting clinical
signs in the 2 groups was the presence of CHF signs
in group B, but not in group A. Group B dogs were
consistent with Harpster class 3 dogs1 and Boxers
with LV systolic dysfunction described by Baum-
wart.15 Mean heart rate was significantly higher in
group B than group A dogs, which would be
consistent with signs of heart failure, due to
sympathetic system activation. The most common
presenting sign in both groups was collapse. This is
similar to the findings of Wotton25 who reported
the presence of syncope in 80% of Boxers with
DCM. In contrast, other studies reported collapse
at much lower rates, 34.3% and 35% respec-
tively.15,1 It would be reasonable to suggest that
syncope in group A would be associated with
ventricular arrhythmias and in this study all dogshad VPCs on ECG/Holter. One study showed that
syncopal dogs had a significantly greater number of
VPCs and grade of arrhythmia, but significant
variability exists and other factors may be involved
in the development of syncope.26 In some Boxers,
VT and bradycardia coexist,27 and without Holter
monitoring (during a collapse), the latter cannot
be excluded as the cause of clinical signs. In
contrast, in group B dogs, VPCs were seen at
a much lower frequency. However a large number
of these dogs still presented with collapse which
might suggest either there were in fact more
ventricular arrhythmias than was documented by
ECG alone (as few subjects had undergone a Holter
study). In our study collapse was significantly and
negatively associated with outcome in group B
dogs. In human patients affected by DCM, syncope
is associated with a significantly increased risk of
sudden death, regardless of the cause of the
proven etiology of the syncope.28 In Boxers,
syncope has been shown to be associated with the
number of VPCs per 24 h and the arrhythmia
grade26 but the predictive value of these findings
has not been examined. In our work association
between presence of VPCs and syncope and
between presence of VT and syncope was not
statistically significant and a correlation with the
number and complexity of the arrhythmia was not
possible because only a small percentage of the
dogs in this study had 24-h Holter monitoring.
However, all the dogs in which a Holter was per-
formed had numerous VPCs per 24 h and frequent
episodes of VT which might suggest that the
prevalence and complexity of ventricular arrhyth-
mias were under-estimated by standard ECG
recordings alone in this group.
The cut-off value to define the normal number
of VPCs in Boxers has not been clearly defined. It is
unusual for mature adult dogs to have ventricular
ectopy, but it has been suggested that a small
number of VPCs may be normal, particularly in an
older dog.29,30 Breed variation may exist and
certain breeds may have a higher number of daily
VPCs. An evaluation of more than 300 adult Boxers
suggested that the finding of more than 100 VPCs/
24 h in an adult Boxer is strongly suggestive of
a diagnosis of ARVC, particularly if there is signif-
icant complexity.3 In our study, in more than half
the cases the Holter classification was reported as
class 4 (>1000 VPCs and presence of couplets,
triplets and VT); this was particularly common in
group A dogs. Holter recordings showed the pres-
ence of VPCs when ECG recordings had been
normal and therefore provided better assessment
of the frequency and complexity of the arrhythmia
where ECG recordings showed only single VPCs.
52 V. Palermo et al.This suggests that Holter monitoring provides the
best assessment of the presence, overall
frequency and complexity of arrhythmias and, in
hindsight, should therefore have been performed
in all affected dogs.
Presence of VT detected by ECG and/or Holter
in dogs with myocardial dysfunction was not asso-
ciated with survival in this study, although close to
statistic significance level. This could be due to the
relatively small number of dogs in our work and the
small percentage of subjects undergoing Holter
monitoring. Complex ventricular arrhythmias are
associated with increased mortality and may
predict sudden death in dogs affected by DCM.31,32
In humans with chronic heart failure, VT is an
independent predictor of mortality33 and VT
lasting longer than 30s may be a negative predictor
in patients with ARVC.34 In Boxer dogs in category 1
and 2, VPCs are often numerous, but often
admixed with runs of VT, thus it is most likely that
fast runs of VT degenerate into ventricular fibril-
lation leading to sudden death.31
The morphology of the VPCs was consistent with
LBBB in the majority of dogs in both groups. In
group A, LBBB morphology was predominant,
whereas in group B whilst LBBB morphology was
common, additionally RBBB or both morphologies
were frequent. The presence of an upright VPC in
lead II, III and aVF (LBBB morphology) is suggestive
of ARVC. On the basis of comparative electro-
physiological studies this morphology is believed
to be associated with a right ventricular origin of
the VPC, although a more precise localization
(septal, apical, outflow tract) has not been
made.3,11 Some of the dogs in this study showed
VPCs consistent with RBBB and some with both
morphologies. Possible explanations are based on
evidence from pace-mapping studies, where
pacing from the right ventricular septum some-
times can produce a RBBB morphology; moreover
the morphology of the QRS complex might be
different depending on whether the initiation is
from the epicardium, mid-myocardium or endo-
cardium.11 Particularly in dogs of group B, RBBB
morphology of the VPCs was more common than in
group A dogs; these subjects had LV dilation, thus
ventricular ectopy arising from the LV may be
possible. In ARVC in humans, when the LV is
affected, ventricular arrhythmias may appear
polymorphic, suggesting an origin from different
cardiac regions.35
While ventricular arrhythmias are characteristic
of the disease, supraventricular arrhythmias have
also been reported.1 AF was not seen in any dogs in
group A but was seen in 13.5% of group B dogs,
probably associated with atrial dilation. Similarresults have been reported by others.1,15,25 AF
seems to be a less common finding in Boxer
cardiomyopathy, whereas it has been reported in
higher percentages (from 30% to 80%) in large-
breed dogs with DCM.36
Left ventricular systolic diameter obtained by
echocardiographic examination was the criterion
for the division of dogs into the two groups. Both
Cornell index20 and ERIs calculations21 confirmed
that LVIDs was in the normal range in all dogs of
group A, while it was over the proposed range in
group B dogs. The latter was particularly important
for the dogs with LVIDs dimension close to the cut-
off chosen (i.e. 36e37 mm). For these reasons we
think our proposed LVIDs cut-off (35 mm) is
reasonable and allows for dogs of different body
weights to be compared in this study.
Although echocardiographic information was
available in only a small number of dogs in Harp-
ster’s report, he reported that all the dogs in
category 3 had LVDs >35 mm and 80% had a FS
<20%2 similar to our group B dogs. In more recent
reports of Boxers with myocardial failure, FS
ranged from 5 to 20%23 and Baumwart reported
a mean FS of 14.4% and a mean LV systolic diam-
eter measured in M-mode of 45 mm.15 Valvular
incompetence was reported in a small number of
dogs in group A, while mitral regurgitation was
a common finding in group B, often in association
with tricuspid regurgitation. Despite the high
percentage of valvular regurgitation in group B,
murmurs were reported in a relatively low
percentage. Possible explanations include under-
reporting in clinical notes or difficulties with
auscultation of brachycephalic dogs with respira-
tory noise. However this might be a normal finding,
as reported in studies involving other breeds of
dogs with DCM.15,37e39
Median survival time was significantly longer in
dogs in group A than in group B, indicating that
once LV dysfunction and congestive heart failure
are present, the prognosis is poor. The median
survival time in group B was similar to survival data
reported by other authors in studies of DCM in
different breeds of dogs36,37 and by Harpster for
Boxers in category 3. For the latter a prognosis of
3e6 months was reported,2 while the prognosis in
categories 1 and 2 tended to be better with many
of the dogs in category 1 doing well for more than 2
years, and dogs in category 2 developing CHF
during the second year.1 Considering that group A
can be representative of both Harpster’s cate-
gories 1 and 2, the results of this study are similar.
In man with ARVC, left ventricular dysfunction was
independently associated with cardiovascular
mortality.40
Cardiomyopathy in Boxer dogs 53The natural history of these dogs with or
without therapy is unknown, although Harpster
reported that 9 dogs treated with an appropriate
antiarrhythmic therapy had a better prognosis.2
Meurs compared the effects of 4 antiarrhythmic
treatments, but the study did not provide infor-
mation on risk of sudden death and long-term
survival. Moreover a direct relationship between
the number and complexity of VPCs and the risk of
sudden death has not been detected10; thus the
ability of a treatment protocol to alter this factor
does not imply an impact on survival.
It is surprising that since 1983, there has not
been a prospective study to follow the clinical
progression and outcome of category 1 & 2 dogs
described by Harpster1 and to determine if these
do progress to category 3 disease. In human ARVC
several steps are recognizable, from an early
clinically “concealed” phase with or without minor
arrhythmias to an “overt electrical heart disorder”
with severe arrhythmias and impending cardiac
arrest to a final stage of “biventricular pump
failure” mimicking dilated cardiomyopathy with
cardiomegaly and congestive heart failure.41
Although dogs have been hypothesized to prog-
ress from category 1e32 objective data supporting
this hypothesis are lacking. Harpster reported that
the majority of dogs in category 2 usually develop
congestive heart failure after one year1 and
Baumwart reported that 4 dogs initially examined
because of ventricular tachyarrhythmias later
developed LV dysfunction.15 In our study most of
the dogs with LV dilation had not previously
undergone cardiac evaluations because they pre-
sented when symptomatic. However, some dogs in
group B did have a long duration of clinical signs
(collapse, exercise intolerance, weakness) prior to
referral. This might be suggestive of Harpster
category 2 (overt) form, which progressed to the
myocardial dysfunction form, which prompted
referral. No dogs were seen to progress from
category 1 or 2 to CHF but most of the dogs with
a normal LV diameter lacked follow-up echocar-
diographic examinations. Thus, these results do
not verify nor refute progression from an
arrhythmia to a left ventricular dysfunction stage.
The natural history of Boxer cardiomyopathy
requires further study. Hopefully more objective
data will be available when a genetic test for the
gene mutation recently discovered9 is developed.
Other studies are needed to confirm that the same
mutation is present in Boxers from Europe and will
clarify if the myocardial dysfunction form is the
expression of the final stage of the disease or the
expression of a different mutation, or of
“conventional” DCM. At present because of theabsence of a perfect diagnostic test, screening
asymptomatic dogs is challenging. Annual Holter
monitoring is recommended in screening of
breeding dogs and significant emphasis on a single
Holter monitoring is discouraged.3 Cardiac
magnetic resonance imaging (MRI) is considered
highly sensitive and specific for the diagnosis of
ARCV in man,42 but in affected Boxers MRI identi-
fied no degenerative fatty changes of the RV
myocardium.43 Cardiac troponin I (cTnI) appeared
to be a better marker than BNP concentration for
ARVC,16,17 but its potential value as a screening
test needs to be assessed.
Limitations of this study include its retrospec-
tive nature, a number of dogs were lost to follow-
up in group A, non-standardization of diagnostic
tests (not all patients underwent Holter moni-
toring), insufficient follow-up echocardiographic
examination, which could have been useful in
monitoring the disease progression and finally the
absence of post-mortem examinations and histo-
logical evaluation, that would have been essential
to confirm the diagnosis, but were often difficult
to obtain because of owners’ reluctance.Conclusion
In conclusion, this study represents a population of
Boxers with cardiomyopathy from the UK. The
majority of dogs, presented with the myocardial
dysfunction form of the disease. Males were
overrepresented, the most common clinical sign
was syncope and in dogs with LV dilation signs of
congestive heart failure were common. Most dogs
either did not have an audible murmur at auscul-
tation or had a low grade murmur. The majority of
dogs had ventricular tachyarrhythmias, particu-
larly with LBBB morphology; AF was not a common
finding and was found only in dogs with a dilated
heart. All the dogs in which a Holter was per-
formed showed various grades of ventricular
arrhythmias, which were often not detected on an
ECG recording. This confirms that ECG has a low
sensitivity for the detection of arrhythmias in
Boxer cardiomyopathy because of their intermit-
tent nature; thus 24-h Holter monitoring provides
the best assessment of presence, overall
frequency and complexity of the arrhythmia and
should be used as part of the diagnosis and for
monitoring treatment in all forms of Boxer
cardiomyopathy. The presence of the myocardial
dysfunction form was associated with a worse
outcome and the presence of syncope in dogs with
myocardial dysfunction was associated with a poor
prognosis.
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